Truscreen to Lodge a Pro Rata Renounceable Rights Issue

12 February 2024
NZX
TruScreen to launch a pro-rata renounceable rights issue
TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or TRU) is pleased to announce its intention to launch
a one (1) for three (3) pro-rata renounceable rights issue to raise up to circa NZD$2.8 million ("Rights Offer”).
An Offer Document will be issued by TruScreen and released to the market in due course. Shareholders
should read the Offer document in full before deciding what actions to take with their rights. Details of the
Rights Offer are as follows:
Rights Offer size
and structure

~NZD$2.8 million pro rata renounceable rights offer to Eligible Shareholders (defined
below) at a ratio of 1 for 3 (Rights Offer). 140,008,446 New fully paid ordinary Shares
in TruScreen (New Shares) will be issued under the Rights Offer.

Rights Offer price NZD$0.02/AUD$0.0187 per New Share (Issue Price)

No Rights trading Rights will not be quoted on the NZX Main Board or the ASX. Holders of Rights shall
be entitled to sell their Rights privately off-market.

Eligibility Only TruScreen shareholders with registered addresses in New Zealand or Australia
on the Record Date will be entitled to participate in the Rights Offer (Eligible
Shareholders).

Oversubscriptions Eligible Shareholders who elect to take up all of their Rights in full will have an
opportunity to apply for additional shares (Shortfall Shares).

Ordinary Shares The New Shares to be issued under the Rights Offer will rank equally in all respects
with the existing ordinary shares on issue in TRU.


The key dates for the Rights Offer are as follows:
Announcement of the Offer

12 February 2024
Record Date for determining Rights 5pm (NZDT)/3pm (AEDT) 20 February 2024

Opening Date for the Offer 21 February 2024

Dispatch of Offer Documents and Entitlement and
Acceptance Forms
On or before 27 February 2024
Closing Date for the Offer 5pm (NZDT)/3pm (AEDT) 13 March 2024

Announcement of results of the Offer 18 March 2024
Allotment of New Shares, despatch of holder
statements and commencement of trading of New
Shares

20 March 2024

The above dates are subject to change at the discretion of TRU, subject to compliance with NZX and ASX
Listing Rules requirements. TRU reserves the right to withdraw the Rights Offer at any time prior to the issue
of New Shares under the Rights Offer at its absolute discretion.

A copy of the Corporate Action Notice and the Cleansing Notice accompany this announcement.


Ends

Tony Ho
Chairman
Tel: +61 41 734 5839
Email: tonyho@truscreen.com











For investor relations queries please visit www.truscreen.com or contact:


Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com


Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures
an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low
level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of
biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel
and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer
screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among
others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized Prevent
and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000* examinations have been performed with TruScreen device. To date,
over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.